Hims & Hers Health Inc.’s stock fell sharply on Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug ...

U.S. stocks were quick to shrug off any early weakness tied to fears of Iranian retaliation after the U.S. bombed the country's key nuclear sites on Saturday. Major indexes quickly erased minor losses ...

German buyout group Mutares said it aims to launch an initial public offering for Terranor Group, a road-maintenance company, on the Nasdaq First North Growth Market in Stockholm later this month.

An analyst issues bullish $421 price target for Coinbase’s stock, while Fiserv’s stock moves up as stablecoin products roll ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Monday's trading session in U.S. stocks kicked off with what appeared to be a remarkably calm tone, even though the state of Iran's nuclear program remains far from clear after this weekend's U.S.

U.S. stocks opened with minor losses Monday, a muted response after President Donald Trump on Saturday ordered a U.S. bombing attack on Iran's nuclear sites. A lack of immediate retaliation by Iran ...

Economist Hyman Minsky argued that stability itself was a destabilizing force in financial markets because it bred ...

If you’re worried about this move being too risky, wait until you see the top asset of those already using a 401(k) brokerage ...

President Donald Trump, in a social-media post Sunday night, said the U.S. bomb attack on Iranian sites a day earlier did "Monumental Damage" as news reports quoted experts calling the status of the ...

Treasury yields were little changed Sunday evening after the U.S. bombed nuclear sites in Iran over the weekend. The yield on the 10-year Treasury note was trading down about 1 basis point at around 4 ...

Shares of Exelixis climbed after the company reported what it called positive topline results from a trail studying a potential treatment for colorectal cancer. The stock jumped 21%, to $48.99, in pre ...